Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARCT | US
0.12
1.42%
Healthcare
Biotechnology
30/06/2024
24/04/2026
8.59
8.52
8.76
8.32
Arcturus Therapeutics Holdings Inc. a late-stage clinical messenger RNA medicines and vaccine company focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC) a mRNA-based therapeutic candidate which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19) a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19 as well as ARCT-032 (LUNAR-CF) a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
26.3%1 month
53.4%3 months
52.9%6 months
60.7%-
2.48
2.21
0.12
0.08
-25.67
2.33
-
-85.67M
232.29M
232.29M
-
-42.37
-
374.00
-26.47
11.77
26.67
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.09
Range1M
2.61
Range3M
2.83
Rel. volume
0.60
Price X volume
2.29M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics Inc | NWBO | Biotechnology | 0.2016 | 252.66M | 5.00% | n/a | 0.00% |
| Editas Medicine Inc | EDIT | Biotechnology | 2.91 | 240.01M | -9.35% | n/a | 16.68% |
| Verastem Inc | VSTM | Biotechnology | 5.91 | 237.84M | -5.14% | n/a | 104.63% |
| BioAtla Inc. | BCAB | Biotechnology | 4.87 | 235.39M | -5.62% | n/a | 5.30% |
| Alector Inc | ALEC | Biotechnology | 2.41 | 234.54M | -0.82% | n/a | 23.98% |
| Abeona Therapeutics Inc | ABEO | Biotechnology | 5.39 | 233.46M | -2.36% | n/a | 31.63% |
| LogicBio Therapeutics Inc | LOGC | Biotechnology | 8.7 | 228.59M | -1.14% | n/a | 0.00% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 15.37 | 227.43M | -0.32% | n/a | 13.35% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 6.5 | 208.55M | -7.67% | n/a | -186.13% |
| Voyager Therapeutics Inc | VYGR | Biotechnology | 3.79 | 206.68M | -6.19% | 29.89 | 13.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 18.17 | 202.74M | 2.83% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.3 | 181.44M | 2.73% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 36.11 | 103.70M | 0.00% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.11 | 99.53M | 1.16% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.765 | 73.67M | 1.69% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.9 | 70.43M | 6.56% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -25.67 | 0.53 | Cheaper |
| Ent. to Revenue | 2.33 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.21 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.92 | 72.80 | Lower Risk |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 232.29M | 3.66B | Emerging |